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OBJECTIVE: We studied the association of Gal-3 and ST2 with early (defined as the period of 90 days post-discharge) rehospitalization and overall mortality, and long-term
overall mortality in HF patients. Additionally, admission aminoterminal B-type natriuretic peptide (NT-proBNP) was considered to test if a multi-marker strategy could yield
supplementary information.
BACKGROUND: The vast data addressing emerging cardiac fibrosis markers as adjunctive to conventional clinical risk factors and natriuretic peptides dosing, led the American
College of Cardiology/ American Heart Association to grant Galectin-3 (Gal-3) and Suppression of Tumorigenicity 2 (ST2) evaluation a class II recommendation for heart failure
(HF) prognosis, in 2013. Yet, in Europe this endorsement is not valid.
PARTNERSHIPS 
 
 
 
 
 
 
 
 
 
 
 
N=65 HF patients
Mean age: 79.2 (SD 10.8)
Median follow-up : 13.7 months
[Q1: 6.7 to Q3: 18.9]
RESULTS
Characteristics Patients (n=65)
Age, mean (SD) 79.2 ± 10.8
Female Gender, n (%) 37 (56.9)
Hypertension, n (%) 58 (89.2)
Type 2 Diabetes, n (%) 25 (38.5)
Dyslipidemia, n (%) 41 (63.1)
Obesity, n (%) 17 (26.2)
Atrial Fibrillation, n (%) 28 (43.1)
Family History of CVD, n (%) 31 (47.7)
Tabagism, n (%) 21 (32.3)
Chronic Kidney Disease, n (%) 34 (52.3)
GFR (Baseline), median 57.8 (43.8 - 82.2)
GFR (Admission), median 47.9 (33.2 - 68.1)
Previous Acute Myocardial Infarction, n (%) 27 (41.5)
Hypertensive Cardiomyopathy, n (%) 44 (67.7)
Ischemic Cardiomyopathy, n (%) 22 (33.8)
Valvular Cardiomyopathy, n (%) 56 (86.2)
LVEF, mean (SD) 50.38 ± 19.07
NYHA class III, n (%) 43 (66.2)
ACE Inhibitor, n (%) 43 (66.2)
Beta Blocker, n (%) 38 (58.5)
Mineralocorticoid Receptor Antagonists, n (%) 19 (29.2)
Angiotensin II Receptor Blocker, n (%) 11 (16.9)
Loop Diuretic, n (%) 54 (83.1)
Digoxin, n (%) 8 (12.3)
Galectin-3, median 9.82 (7.94 -12.00)
ST2, median 27.22 (15.45-44.39)
NT-proBNP (Admission), median 5701.0 (1867 - 11961)
Values are median (IQR), n (%), or mean ± SD. IQR: interquartile range and minimum/maximum, SD: standard deviation, 
CVD: cardiovascular disease, GFR: glomerular filtration rate, ACE: Angiotensin-Converting-Enzyme.
METHODS: Gal-3, ST2 and NT-proBNP were assessed in patients hospitalized, to an Internal Medicine ward, with acute decompensated HF in class III or IV of New York Heart
Association (NYHA). Subgroup analysis was performed according to the left ventricular ejection fraction (LVEF) in light of the current European Society of Cardiology guidelines.
Comparison between patients with and without each of the events was performed for all variables using t test or Wilcoxon Rank test as applicable. Categorical variables were
summarized by relative and absolute frequencies, and compared using chi-squared test or Fisher’s Exact test as applicable. Univariate Cox proportional hazard model was used to
assess the relationship between variables and outcomes. Since there are no standardized cut-offs for Gal-3 and ST2, the multiclass Area Under the Curve Receiver-Operator
Characteristic (AUCROC) as defined by Hand and Till was used to evaluate the overall performance of each biomarker as a predictor of the outcomes. The Spearman’s correlation
coefficient was used to determine the relationship between variables.
CONCLUSION:
- High Gal-3 determinations correlated with early rehospitalization, early mortality and long-term mortality; whereas ST2 predicted long-term mortality.
- Combined analysis with elevated NT-proBNP values further increased the outcomes’ risk.
- Our findings support the assumption that promising novel biomarkers Gal-3 and ST2 may be useful for HF risk stratification.
- Furthermore, a multi-marker strategy appears to add information, as a synergism between natriuretic peptides and the cited biomarkers was documented.
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Figure 1 - Short-term mortality - Kaplan Meier: GAL3 ≥10.97 ng/mL Figure 2 - Long-term mortality - Kaplan Meier: GAL3 ≥9.99 ng/mL Figure 3 - Long-term mortality - Kaplan Meier: sST2 ≥24.78 pg/mL
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HR 95% CI P value
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GALECTIN-3 & NT-proBNP
Characteristic
Early rehospitalization
Early death
Long-term mortality
HR 95% CI P value
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• Spearman's correlation indicated a 
significant negative relation between:
• ST2 levels and baseline GFR 
(Coefficient: -0.418, P<0.001)
• ST2 levels and admission GFR 
(Coefficient: -0.438, P<0.001). 
• An association between ST2 and long-term mortality was
acknowledged (HR: 4.846, 95% CI: 1.396-16.825, P-value=0.013).
sST2 ≥24.78pg/mL 
and
Admission NT-proBNP ≥21336ng/L 
HR: 5.953, 95% CI: 1.683-21.055, P-value=0.006
sST2 ≥24.78pg/mL
and
Gal-3 ≥9.99 ng/mL 
HR: 6.209, 95% CI: 2.393-16.114, P-value<0.001
Long-term mortality
Gal-3 ≥9.99 ng/mL 
and
sST2 ≥24.78pg/mL
HR: 15.782, 95% CI: 1.593-156.322, P-value=0.018
Long-term mortality for HFrEF Long-term mortality for HFpEF
HR: 5.2, 95% CI: 1.223-22.187, P-value=0.026
Gal-3 ≥9.99 ng/mL 
and
sST2 ≥24.78pg/mL
